Molecular characterization of Neisseria gonorrhoeae on non-cultured specimens from multiple anatomic sites

Anna Carannante1, Valeria Ghisetti2, Ivano Dal Conte3, Gabriella Gregori2, Maria Laura Stella4, Paola Vacca1, Simonetta Del Re2 and Paola Stefanelli1

1Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
2Dipartimento di Malattie Infettive, Laboratorio di Microbiologia e Virologia, Ospedale Amedeo di Savoia, Turin, Italy
3Dipartimento di Malattie Infettive, Ambulatorio IST, Ospedale Amedeo di Savoia, Turin, Italy
4Dipartimento di Malattie Infettive, Università di Torino, Turin, Italy

Abstract
Introduction. The aim of this study was to molecularly characterize Neisseria gonorrhoeae on non-cultured specimens collected from multiple anatomic sites. N. gonorrhoeae multiantigen sequence typing (NG-MAST) together with the gene sequence analysis of antimicrobial resistance (AMR) target genes were used.

Materials and methods. Seventeen genital and extra-genital samples from eight patients (7 were men who have sex with men, MSM, and 1 women who have sex with men, WSM) with gonorrhoea symptoms were analyzed. For 7, of the 8 patients, conventional culture method has been used to identify gonorrhoea. All the samples were tested with the rapid molecular method CEPHEID. Amplification and sequencing of porB and tbpB, to identify the Sequence Type (ST) by NG-MAST, and penA, mtrR, porB1b, ponA genes were also performed. Antimicrobial susceptibility by Etest, for the available culture positive samples, was carried out.

Results. For 7 patients the ST was obtained and for 6 the complete sequence analysis of the AMR target genes was also defined. For the majority of them, samples collected from multiple sites (oropharynx, rectum, vaginal and urethra) confirm the presence of the same gonorrhoea strain. In particular, for 5 patients the same STs and changes in the AMR target genes were identified.

Conclusion. Molecular characterization on non-cultured or culture negative specimens for gonorrhoea can successfully be applied directly to genital and extra-genital samples. Thus permit to identify the presence of the same strain in patients with gonorrhoea infection in multiple anatomic sites and to predict the antimicrobial susceptibility pattern.

INTRODUCTION
Neisseria gonorrhoeae (NG) infection is nowadays considered a public health issue at international level [1].

The diagnosis of gonorrhoea consists in the cultivation of the pathogen, as a gold standard, and/or the identification of DNA by nucleic acid amplification tests (NAATs) [2]. NAATs are approximately twice as sensitive as culture on oropharyngeal specimens [3, 4], however, it could generate false-positive results due to the presence of other Neisseria species in the oropharynx [5].

N. gonorrhoeae multiantigen sequence typing (NG-MAST) is routinely used in gonorrhoea typing system for its discriminatory power and international comparison [6]. In addition, molecular typing permits to monitor the circulation of specific NG clones, as e.g. the genogroup (G) 1407, an international multi-drug resistant gonococcal strain with decreased susceptibility or resistance to cefixime, ceftriaxone and azithromycin, and resistance to ciprofloxacin [7, 8].

Moreover, the analysis of antimicrobial resistance (AMR) target genes is crucial for enhancing gonococcal AMR (GONO-AMR) surveillance. Several mechanisms have been extensively described to be associated with resistance in gonorrhoea. From them, changes of penA gene (encoding the penicillin-binding protein 2-PBP2) were responsible for decreased susceptibility or resistance to extended-spectrum cephalosporin (ESCs) [9].
Additionally, overexpression of the MtrCDE efflux pump, due to mutations in the promoter and coding region of the mtrR gene, together with the decreased membrane permeability caused by porB1b gene mutations, contribute to the decreased susceptibility and resistance to ESCs [9]. The role of other genes associated with penicillin resistance, as e.g., ponA gene (encoding penicillin-binding protein 1-PBP1), remains unclear.

The object of this study was to identify the same gonococcal strain in patients, mainly men who have sex with men (MSM), in multiple anatomic sites and to type them by NG-MAST and by gene sequencing of penA, mtrR, porB1b and ponA genes known to be involved in the AMR in gonorrhoea, even with the lack of cultivated strain.

**MATERIALS AND METHODS**

**Samples**

Seventeen clinical samples (genital and extra-genital), collected, in 2014, from eight patients with symptoms of gonorrhoea (urethritis and/or proctitis or cervicitis; no one had overtly symptomatic pharyngitis) at the STI Clinic, Amedeo di Savoia Hospital, Turin, Italy, resulting negative or positive by culture and samples not cultured at all, were analyzed. For six patients, pharyngeal and rectal paired samples were collected; in one, an urethral sample was also gathered. In two patients pharyngeal swabs were paired with urethral and vaginal samples.

For three samples (gathered at pharyngeal, rectal and urethral sites), collected from the same patient, the culture was not performed at all. All the remaining pharyngeal samples were culture-negative. Among the residual 5 rectal samples, only two were culture-positive and the vaginal together with the remaining urethral samples were culture-negative and culture-positive, respectively.

Patient clinical data were anonymously collected for surveillance purposes, thus no ethical approval was required.

**Nucleic acid amplification test (NAAT) for CT/NG**

Swabs were collected in Xpert CT/NG (*Chlamydia trachomatis/Neisseria gonorrhoeae*) Swab Transport Reagent tubes and processed with the Xpert CT/NG Assay (Cepheid, SystemsCepheid Europe SAS, Mauritius-Scopont France), that is an automated in vitro diagnostic test for the qualitative detection and differentiation of DNA from CT and NG. The assay was performed on the Cepheid GeneXpert Instrument that integrates sample purification, nucleic acid extraction, amplification and detection of the target sequences using real-time PCR platform [10].

**NG-MAST, penA, mtrR, porB1b, ponA analyses**

A total of 17 samples resulting positive by CEPHEID, were then sent to Istituto Superiore di Sanità (ISS) for molecular characterization.

DNA was purified using QIAamp DNA minikit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.

Genes for *penA*, *mtrR*, *porB1b*, *ponA* genes and *porB* and *tbpB* for the NG-MAST analysis, were amplified using primers and amplification parameters, as already described [6, 9, 11].

Thermocycling for PCR was performed using Veriti 96 well instrument, (Applied Biosystems). Samples not successfully amplified in the initial reaction, were subsequently re-tested in a temperature gradient amplification program with the following cycling condition: 95 °C for 15 min, followed by 30 cycles of 94 °C for 1 min, 65 °C for 1 min and 72 °C for 2 min with decreasing 0.5 °C per cycle, followed by 10 cycles of 94 °C for 1 min, 50 °C for 1 min and 72 °C for 2 min; and a final extension step of 72 °C for 2 min.

The *porB* and *tbpB* alleles were analyzed at the NG-MAST website (www.ng-mast.net). Closely related STs were clustered using published definitions as well as those belonging to the same genogroup [8].

Multiple sequence and amino acid alignments were performed using CromasPro version 1.15 and Clustal Omega web site (www.ebi.ac.uk/Tools/msa/clustalo/).

**Antimicrobial susceptibility**

A total of three strains, isolated from three patients, were collected from rectal (n = 2) and urethral (n = 1) sites. After growth on Thayer-Martin medium (Oxoid Ltd, Italy) with 1% IsoVitalex (Oxoid, Ltd) at 37 °C in a 5% CO2 atmosphere, antimicrobial susceptibility tests have been performed following the European Gonococcal Antimicrobial Surveillance Programme (EUROGASP) [12].

In particular, antimicrobial susceptibility to cefixime, ceftriaxone, ciprofloxacin and azithromycin was assessed by Etest (bioMérieux, Sweden), carried out in agreement with the manufacturer’s instructions. World Health Organization (WHO) *N. gonorrhoeae* G, K, M, O, and P control strains were added in the assay [13].

**RESULTS**

**Samples and patients**

A total of 17 samples, from eight patients, were lab-confirmed by CEPHEID. All of them were symptomatic with urethritis and/or proctitis or cervicitis but none had overtly symptomatic pharyngitis.

The patient’s nationality was as following: six Italians, one Rumanian and one Brazilian and the median age was of 26.6 years (years range 19-42). Seven were MSM and one women who have sex with men (WSM). All the patients denied sexual contacts outside the city of Turin; three of them had a previous gonococcal infection and none was HIV positive. The WSM patient was co-infected with *Trichomonas vaginalis* (data not shown). The patients were treated with a combined therapy of 0.5 g of intramuscular ceftriaxone plus 1 g of oral azithromycin.

**Molecular analyses**

For all samples, except for one collected from pharynx, it was possible to assign the *porB* and *tbpB* alleles (*Table 1*). The same Sequence Type (ST) was found in all paired samples except for one couple (ID8a, pharyngeal, and 8b, urethral) showing different *porB* and *tbpB* alleles (*Table 1*). In particular, as showed in *Table 1*, the ST292,
An Analysis of non-cultured gonorrhoea

Original articles and reviews

ST1352, ST5624 (belonging to G5624), ST11632 (belonging to G4995), ST2400 (belonging to G2400), ST10259, ST9909 and ST1935 have been assigned.

The penA sequences were compared with N. gonorrhoeae LM306 (Accession number: M32091) and N. gonorrhoeae NG-3 (Accession number AB071984).

As shown in Table 1, all samples showed penA non-mosaic allele containing an aspartic acid insertion at position 345 (D345a). In particular, 3 paired samples, ID1a and 1b, 3a and 3b, 4a and 4b, and samples ID7a, 7b and 7c showed the same nonmosaic type IV allele.

The nonmosaic type IV allele with two additional amino acid substitutions, A501T and P551L (Accession number: KP677512, [14]) was identified in ID5a and 5b paired samples. The sample with ID8b showed penA nonmosaic allele V with the additional substitution V501T.

The amino acid substitution was not determined for ID8a (Table 1). No amplification of penA gene was obtained in two paired samples ID2a and 2b, 6a and 6b, respectively.

mtrR gene harbored the single adenine deletion in the promoter region and the T86A, H105Y, D79N amino acid changes in the MtrR efflux pump in ID4a and 4b, 5a and 5b, 8a and 8b. ID4a and 4b showed the G45D amino acid change in the MtrR DNA-binding motif; ID7a, 7b, 7c showed the A39T amino acid change and ID3a and 3b samples harboured an insertion of adenine at position 17 from the ATG of the gene (Table 1). Two paired samples, ID2a and 2b, 6a and 6b, were negative for mtrR amplification reaction.

The L421P amino acid substitution in the porA allele was detected in six couple of samples and in the urethra sample ID8b (Table 1). Moreover, samples with ID2a and 2b and ID6b were negatives for porA amplification reaction.

The amino acid substitutions A121S was found in PorB1b for three paired samples (ID1a and 1b, 2a and 2b, 4a and 4b); G120D and A121G was detected in one couple of samples (ID3a and 3b) and G120K and A121D in two paired samples (ID5a and 5b, 6a and 6b) (Table 1). ID8a and 8b showed different amino acid substitutions: A121D and G120K together with A121D, respectively.

Antimicrobial susceptibility assay results on three cultivated strains were in agreement with the mutation identify in the target genes analyzed in samples collected from the same patients. They were strains cultivated from the samples ID4b, 6b and 8b. The results were as follows: susceptible to cefixime (MIC range values 0.016-0.023 mg/L) and ceftriaxone (MIC range values 0.002-0.023 mg/L); resistant to ciprofloxacin (MIC range values 4-12 mg/L). ID4b and 6b showed a decreased susceptibility to azithromycin with MIC = 0.38 mg/L and 0.25 mg/L and respectively. Moreover, ID8b was resistant to azithromycin with MIC = 1.5 mg/L.

### Table 1

| ID | Specimen site | Sex | Sexual orientation | Patient age, years | NG-MAST | ST | penA | mtrR | ponA | porB1b
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GAC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>21</td>
<td>28</td>
<td>4</td>
<td>ST292</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>1b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td>4</td>
<td>ST292</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>2a</td>
<td>Oropharynx</td>
<td>F</td>
<td>WSM</td>
<td>26</td>
<td>301</td>
<td>4</td>
<td>ST1352</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2b</td>
<td>Vaginal</td>
<td></td>
<td></td>
<td></td>
<td>301</td>
<td>4</td>
<td>ST1352</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>3a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>28</td>
<td>90</td>
<td>93</td>
<td>ST5624</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>3b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>90</td>
<td>93</td>
<td>ST5624</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>4a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>21</td>
<td>6816</td>
<td>33</td>
<td>ST11632</td>
<td>N'</td>
<td>D345a</td>
<td>A-deletion*</td>
</tr>
<tr>
<td>4b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>6816</td>
<td>33</td>
<td>ST11632</td>
<td>N'</td>
<td>D345a</td>
<td>A-deletion*</td>
</tr>
<tr>
<td>5a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>31</td>
<td>1489</td>
<td>563</td>
<td>ST2400</td>
<td>N'</td>
<td>D345a</td>
<td>A-deletion*</td>
</tr>
<tr>
<td>5b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>1489</td>
<td>563</td>
<td>ST2400</td>
<td>N'</td>
<td>D345a</td>
<td>A-deletion*</td>
</tr>
<tr>
<td>6a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>42</td>
<td>1489</td>
<td>4</td>
<td>ST10259</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>1489</td>
<td>4</td>
<td>ST10259</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>7a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>19</td>
<td>5853</td>
<td>241</td>
<td>ST9099</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>7b</td>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td>5853</td>
<td>241</td>
<td>ST9099</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>7c</td>
<td>Urethra</td>
<td></td>
<td></td>
<td></td>
<td>5853</td>
<td>241</td>
<td>ST9099</td>
<td>N'</td>
<td>D345a</td>
<td>wt</td>
</tr>
<tr>
<td>8a</td>
<td>Oropharynx</td>
<td>M</td>
<td>MSM</td>
<td>25</td>
<td>870</td>
<td>1005^</td>
<td>-</td>
<td>NA</td>
<td>-</td>
<td>A-deletion*</td>
</tr>
<tr>
<td>8b</td>
<td>Urethra</td>
<td></td>
<td></td>
<td></td>
<td>182</td>
<td>4</td>
<td>ST1935</td>
<td>V'</td>
<td>A301T</td>
<td>D345a</td>
</tr>
</tbody>
</table>

* = new penA sequence pattern, accession number KP677512 [15]
** = adenine (A) insertion at nt 17 from ATG of mtrR gene
° = adenine (A) deletion in the mtrR promoter
^ = 96% of similarity with the mtrR allele 1005
Wt = wild-type
MSM = men who have sex with men
WSM = women who have sex with men
NA = not applicable
DISCUSSION

Gonococcal infection is nowadays a worrisome reality due to the circulation of AMR and of multi-drug resistant (MDR) strains [15]. In this context, it is crucial to define the patterns of antimicrobial susceptibility and to genotype those samples resulting negative by culture or samples not cultured at all [16]. Since the spread in the use of molecular techniques to identify the presence of gonorrhoea without a culture confirmation, it is essential to be able to predict at least the antimicrobial susceptibility. In order to answer to this request we analyzed 17 samples collected from several anatomic sites from 8 patients.

The analysis of *penA* gene showed the presence of nonmosaic type IV allele. It has been already described to be associated with ESC susceptible profile in NG [9, 11] and recovered in Italy in cefixime susceptible NG [14]. Sustaining this point the T86A, H105Y, D79N, A397 in the MtrR efflux pump and the A121S, A121G, A121D, G120D, G120K amino acid changes in PorB1b were found [15, 17].

Moreover, STs belonging to G2400, found in the samples ID5a and 5b, showed *penA* nonmosaic allele IV variant with two additional amino acid substitutions (A501T and P551L), the substitutions D79N/T86A/ H105Y in MtrR, the L421P in PBP1 and G120K/ A121D in PorB1b, as already described [14]. For a MSM patient, two *N. gonorrhoeae* strains, one in the pharynx and one in the urethra, with different *porB* and *tpbB* alleles and two molecular profiles for antimicrobial resistant determinants were found. From the urethra it was possible to cultivate the strain confirming the resistance to ciprofloxacin and the susceptibility to cefixime as observed by the molecular analysis on sample.

CONCLUSION

In summary, we display the molecular characterization of gonorrhoea non-cultured or culture-negative.

In the panel of samples analyzed it was possible to characterize the presence of DNA associated to the same gonococcal strain and to predict the susceptibility to the antimicrobials in use for gonorrhoea therapy.

Since the large use of molecular methods for laboratory diagnosis of gonorrhoea the possibility to detect antimicrobial resistance genes provide an alternative to culture-based antimicrobial susceptibility testing especially in the era of global spreading of gonococci resistant or multidrug resistant to antimicrobials.

Funding

The collection of *Neisseria gonorrhoeae* isolates was supported by Ministry of Health-CCM Project 2014 “Sorveglianza delle Infezioni Sessualmente Trasmesse (IST) attraverso due reti sentinella basati su centri clinici e su laboratori di microbiologia clinica, e Sorveglianza di laboratorio della farmaco resistenza di *Neisseria gonorrhoeae* come malattia emergente”.

Acknowledgments

The authors thank Luigina Ambrosio for technical assistance.

Authors’ contributions

AC, performed NG-MAST and resistance target genes analyses and drafted the manuscript. VG, IDC, GG, MLS and SDR, collected the samples together with the clinical data of patients and performed the NAATs analysis. PV, performed the DNA extraction and sequence analysis. PS, designed the study and drafted the manuscript. All authors approved the final version of the manuscript.

Conflict of interest statement

None to declare.

Received on 10 February 2017. Accepted on 11 May 2017.

REFERENCES


9. Lee SG, Lee H, Jeong SH, Yong D, Chung GT, Lee YS, Chong Y, Lee K. Various *penA* mutations together with *mtrR*, *porB* and *penA* mutations in *Neisseria gonorrhoeae* isolates with reduced susceptibility to cefixime or cep-